Teslascan

Country: European Union

Language: Estonian

Source: EMA (European Medicines Agency)

Buy It Now

Patient Information leaflet Patient Information leaflet (PIL)
02-08-2012
Summary of Product characteristics Summary of Product characteristics (SPC)
02-08-2012
Public Assessment Report Public Assessment Report (PAR)
02-08-2012

Active ingredient:

mangafodipiini trinaatrium

Available from:

GE Healthcare AS

ATC code:

V08CA05

INN (International Name):

mangafodipir

Therapeutic group:

Kontrastsusmeedium

Therapeutic area:

Magnetresonantstomograafia

Therapeutic indications:

See ravim on mõeldud ainult diagnostiliseks kasutamiseks. Seevastu keskmise diagnostika magnetresonantstomograafia (MRI) avastamiseks kahjustused maksa kahtlus, et need võivad olla tingitud metastaatilise haiguse või hepatotsellulaarne kartsinoomide. Lisandina, et MRI abi uurimise keskuse pankrease kahjustused.

Product summary:

Revision: 9

Authorization status:

Endassetõmbunud

Authorization date:

1997-05-22

Patient Information leaflet

                                Ravimil on müügiluba lõppenud
European Medicines Agency
7 Westferry Circus, Canary Wharf, London E14 4HB, UK
Tel. (44-20) 74 18 84 00 Fax (44-20) 74 18 84 16
E-mail: mail@emea.europa.eu http://www.emea.europa.eu
©
EMEA 2007 Reproduction and/or distribution of this document is
authorised for non commercial purposes only provided the EMEA is
acknowledged
EMEA/H/C/137
EUROOPA AVALIK HINDAMISARUANNE
TESLASCAN
KOKKUVÕTE ÜLDSUSELE
_Käesolev dokument on Euroopa avaliku hindamisaruande kokkuvõte.
Selles _
_selgitatakse, kuidas _
_inimtervishoius kasutatavate ravimite komitee hindas teostatud
uuringuid, et koostada soovitused _
_ravimi kasutamise kohta._
_Kui vajate oma haigusseisundi või ravi osas asjakohast lisateavet,
lugege palun pakendi infolehte _
_(mis _
_on _
_samuti _
_Euroo_
_pa _
_avaliku _
_hindamisaruande _
_osa) _
_või _
_võtke _
_ühendust _
_oma _
_arsti _
_või _
_apteekriga. Kui soovite lisateavet inimtervishoius kasutatavate
ravimite komitee soovituste aluse _
_kohta, lugege palun teadusliku arutelu kokkuvõtet (samuti Euroopa
avaliku hindamisaruande _
_osa)._
MIS ON TESLASCAN?_ _
TESLASCAN on infusioonilahus (veeni tilgutamiseks), mille toimeaine on
mangafodipiirtrinaatrium.
MILLEKS TESLASCANI KASUTATAKSE?
TESLASCAN on ette nähtud kasutamiseks diagnostikas. TESLASCANi
kasutatakse patsientidel,
kellele tehak
se magnetresonantstomograafia (MRI) maksa koekahjustuste avastamiseks,
mis võivad
olla põhjustatud maksavähist või muudest kehaosadest maksa levinud
vähist. TESLASCAN on
kontrastaine, mis võimaldab saada selgema kujutise. TESLASCANi võib
kasutada magnetresonants-
tomograafias ka kõhunäärme kahjustuste uurimiseks.
Seda ravimit saab üksnes retsepti alusel.
KUIDAS TESLASCANI KASUTATAKSE?
TESLASCANi
manustatakse
ühekordse
intravenoosse
infusioonina
annuses
0,5
ml
kehakaalu
kilogrammi kohta. Infusioonikiirus on maksauuringute korral 2–3
ml/min ja kõhunäärmeuuringute
korral 4–6 ml/min. Kujutise kontrastsuse paranemine algab 15–20
minuti möödumisel infusiooni
algusest ja 
                                
                                Read the complete document

Summary of Product characteristics

                                Ravimil on müügiluba lõppenud
European Medicines Agency
7 Westferry Circus, Canary Wharf, London E14 4HB, UK
Tel. (44-20) 74 18 84 00 Fax (44-20) 74 18 84 16
E-mail: mail@emea.europa.eu http://www.emea.europa.eu
©
EMEA 2007 Reproduction and/or distribution of this document is
authorised for non commercial purposes only provided the EMEA is
acknowledged
EMEA/H/C/137
EUROOPA AVALIK HINDAMISARUANNE
TESLASCAN
KOKKUVÕTE ÜLDSUSELE
_Käesolev dokument on Euroopa avaliku hindamisaruande kokkuvõte.
Selles _
_selgitatakse, kuidas _
_inimtervishoius kasutatavate ravimite komitee hindas teostatud
uuringuid, et koostada soovitused _
_ravimi kasutamise kohta._
_Kui vajate oma haigusseisundi või ravi osas asjakohast lisateavet,
lugege palun pakendi infolehte _
_(mis _
_on _
_samuti _
_Euroo_
_pa _
_avaliku _
_hindamisaruande _
_osa) _
_või _
_võtke _
_ühendust _
_oma _
_arsti _
_või _
_apteekriga. Kui soovite lisateavet inimtervishoius kasutatavate
ravimite komitee soovituste aluse _
_kohta, lugege palun teadusliku arutelu kokkuvõtet (samuti Euroopa
avaliku hindamisaruande _
_osa)._
MIS ON TESLASCAN?_ _
TESLASCAN on infusioonilahus (veeni tilgutamiseks), mille toimeaine on
mangafodipiirtrinaatrium.
MILLEKS TESLASCANI KASUTATAKSE?
TESLASCAN on ette nähtud kasutamiseks diagnostikas. TESLASCANi
kasutatakse patsientidel,
kellele tehak
se magnetresonantstomograafia (MRI) maksa koekahjustuste avastamiseks,
mis võivad
olla põhjustatud maksavähist või muudest kehaosadest maksa levinud
vähist. TESLASCAN on
kontrastaine, mis võimaldab saada selgema kujutise. TESLASCANi võib
kasutada magnetresonants-
tomograafias ka kõhunäärme kahjustuste uurimiseks.
Seda ravimit saab üksnes retsepti alusel.
KUIDAS TESLASCANI KASUTATAKSE?
TESLASCANi
manustatakse
ühekordse
intravenoosse
infusioonina
annuses
0,5
ml
kehakaalu
kilogrammi kohta. Infusioonikiirus on maksauuringute korral 2–3
ml/min ja kõhunäärmeuuringute
korral 4–6 ml/min. Kujutise kontrastsuse paranemine algab 15–20
minuti möödumisel infusiooni
algusest ja 
                                
                                Read the complete document

Similar products

Active ingredient mangafodipiini trinaatrium

mangafodipiini trinaatrium

ATC code V08CA05

V08CA05

Marketed by GE Healthcare AS

GE Healthcare AS

INN (International Name) mangafodipir

mangafodipir

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 02-08-2012
Summary of Product characteristics Summary of Product characteristics Bulgarian 02-08-2012
Public Assessment Report Public Assessment Report Bulgarian 02-08-2012
Patient Information leaflet Patient Information leaflet Spanish 02-08-2012
Summary of Product characteristics Summary of Product characteristics Spanish 02-08-2012
Public Assessment Report Public Assessment Report Spanish 02-08-2012
Patient Information leaflet Patient Information leaflet Czech 02-08-2012
Summary of Product characteristics Summary of Product characteristics Czech 02-08-2012
Public Assessment Report Public Assessment Report Czech 02-08-2012
Patient Information leaflet Patient Information leaflet Danish 02-08-2012
Summary of Product characteristics Summary of Product characteristics Danish 02-08-2012
Public Assessment Report Public Assessment Report Danish 02-08-2012
Patient Information leaflet Patient Information leaflet German 02-08-2012
Summary of Product characteristics Summary of Product characteristics German 02-08-2012
Public Assessment Report Public Assessment Report German 02-08-2012
Patient Information leaflet Patient Information leaflet Greek 02-08-2012
Summary of Product characteristics Summary of Product characteristics Greek 02-08-2012
Public Assessment Report Public Assessment Report Greek 02-08-2012
Patient Information leaflet Patient Information leaflet English 02-08-2012
Summary of Product characteristics Summary of Product characteristics English 02-08-2012
Public Assessment Report Public Assessment Report English 02-08-2012
Patient Information leaflet Patient Information leaflet French 02-08-2012
Summary of Product characteristics Summary of Product characteristics French 02-08-2012
Public Assessment Report Public Assessment Report French 02-08-2012
Patient Information leaflet Patient Information leaflet Italian 02-08-2012
Summary of Product characteristics Summary of Product characteristics Italian 02-08-2012
Public Assessment Report Public Assessment Report Italian 02-08-2012
Patient Information leaflet Patient Information leaflet Latvian 02-08-2012
Summary of Product characteristics Summary of Product characteristics Latvian 02-08-2012
Public Assessment Report Public Assessment Report Latvian 02-08-2012
Patient Information leaflet Patient Information leaflet Lithuanian 02-08-2012
Summary of Product characteristics Summary of Product characteristics Lithuanian 02-08-2012
Public Assessment Report Public Assessment Report Lithuanian 02-08-2012
Patient Information leaflet Patient Information leaflet Hungarian 02-08-2012
Summary of Product characteristics Summary of Product characteristics Hungarian 02-08-2012
Public Assessment Report Public Assessment Report Hungarian 02-08-2012
Patient Information leaflet Patient Information leaflet Maltese 02-08-2012
Summary of Product characteristics Summary of Product characteristics Maltese 02-08-2012
Public Assessment Report Public Assessment Report Maltese 02-08-2012
Patient Information leaflet Patient Information leaflet Dutch 02-08-2012
Summary of Product characteristics Summary of Product characteristics Dutch 02-08-2012
Public Assessment Report Public Assessment Report Dutch 02-08-2012
Patient Information leaflet Patient Information leaflet Polish 02-08-2012
Summary of Product characteristics Summary of Product characteristics Polish 02-08-2012
Public Assessment Report Public Assessment Report Polish 02-08-2012
Patient Information leaflet Patient Information leaflet Portuguese 02-08-2012
Summary of Product characteristics Summary of Product characteristics Portuguese 02-08-2012
Public Assessment Report Public Assessment Report Portuguese 02-08-2012
Patient Information leaflet Patient Information leaflet Romanian 02-08-2012
Summary of Product characteristics Summary of Product characteristics Romanian 02-08-2012
Public Assessment Report Public Assessment Report Romanian 02-08-2012
Patient Information leaflet Patient Information leaflet Slovak 02-08-2012
Summary of Product characteristics Summary of Product characteristics Slovak 02-08-2012
Public Assessment Report Public Assessment Report Slovak 02-08-2012
Patient Information leaflet Patient Information leaflet Slovenian 02-08-2012
Summary of Product characteristics Summary of Product characteristics Slovenian 02-08-2012
Public Assessment Report Public Assessment Report Slovenian 02-08-2012
Patient Information leaflet Patient Information leaflet Finnish 02-08-2012
Summary of Product characteristics Summary of Product characteristics Finnish 02-08-2012
Public Assessment Report Public Assessment Report Finnish 02-08-2012
Patient Information leaflet Patient Information leaflet Swedish 02-08-2012
Summary of Product characteristics Summary of Product characteristics Swedish 02-08-2012
Public Assessment Report Public Assessment Report Swedish 02-08-2012

Search alerts related to this product

Alerts Teslascan mangafodipiini trinaatrium mangafodipir

Teslascan mangafodipiini trinaatrium mangafodipir

View documents history

Documents history Documents history

Teslascan